title: Hyperbaric oxygenation ameliorates indomethacin-induced enteropathy in rats by modulating TNF-alpha and IL-1beta production.
abstract: The effect of hyperbaric oxygenation (HBO2) was investigated in a rat model of indomethacin-induced enteropathy. Enteropathy was induced by two subcutaneous injections of indomethacin (7.5 mg/kg) 24 hr apart. Six groups of rats (n=8) were treated with and without HBO2 (100% oxygen at 2.3 atm absolute) for 1 hr once or twice a day for 2 or 5 days. Disease activity index (DAI) and total ulcer length were measured. Other rats were randomized into two groups (n=16) with and without HBO2 (1 hr once a day) and four rats were killed in each group at 12, 24, 48, and 72 hr after the final injection of indomethacin. Serum and intestinal mucosal TNF-alpha, IL-1beta, myeloperoxidase (MPO), and iNOS expression was measured. HBO2 treatment significantly attenuated indomethacin -induced intestinal ulceration and improved DAI. Indomethacin increased MPO activity and iNOS expression, and these were reduced by HBO2 treatment, with a concomitant reduction in TNF-alpha and IL-1beta. Our data suggest that HBO2 treatment has a beneficial effect on indomethacin-induced enteropathy and this effect is possibly mediated by decreased production of TNF-alpha and IL-1beta.
authors.affiliation: Research Laboratory, Department of Anesthesiology, SUNY Upstate Medical University, Syracuse, New York 13210, USA. yangz@upstate.edu
authors.forename: Z
authors.initials: Z
authors.lastname: Yang
authors.forename: J
authors.initials: J
authors.lastname: Nandi
authors.forename: J
authors.initials: J
authors.lastname: Wang
authors.forename: G
authors.initials: G
authors.lastname: Bosco
authors.forename: M
authors.initials: M
authors.lastname: Gregory
authors.forename: C
authors.initials: C
authors.lastname: Chung
authors.forename: Y
authors.initials: Y
authors.lastname: Xie
authors.forename: X
authors.initials: X
authors.lastname: Yang
authors.forename: E M
authors.initials: EM
authors.lastname: Camporesi
mesh_terms: D000818:Animals; D015415:Biomarkers / Q000097:blood; D004195:Disease Models, Animal; D018450:Disease Progression; D004591:Electrophoresis, Polyacrylamide Gel; D006931:Hyperbaric Oxygenation; D007213:Indomethacin / Q000633:toxicity; D007375:Interleukin-1 / Q000096:biosynthesis*; D007410:Intestinal Diseases / Q000139:chemically induced / Q000378:metabolism / Q000628:therapy*; D007413:Intestinal Mucosa / Q000187:drug effects / Q000378:metabolism; D008297:Male; D052247:Nitric Oxide Synthase Type II / Q000096:biosynthesis; D009195:Peroxidase / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis*; D014456:Ulcer / Q000139:chemically induced / Q000378:metabolism / Q000628:therapy*
chemical_list: D015415:Biomarkers; D007375:Interleukin-1; D014409:Tumor Necrosis Factor-alpha; D009195:Peroxidase; D052247:Nitric Oxide Synthase Type II; D007213:Indomethacin